Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects With Advanced Refractory Solid Tumor Malignancies

What is the purpose of this trial?

JTX-2011-101 is a Phase 1/2, open label, dose escalation and expansion clinical study of JTX-2011 alone or in combination with a fixed dose of nivolumab in subjects with advanced solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.


Participation Guidelines

Ages: 18 years and older

Gender: Both


Jounce Therapeutics

Dates: 04/12/2017 - 05/30/2018

Last Updated: 04/13/2017

Study HIC#: 1606017922

Get Involved

For more information about this study, contact:
Jacqueline Rollin
+1 203-859-0001
jacqueline.rollin@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image